WC
BCYC

Wexford Capital’s Bicycle Therapeutics BCYC Stock Holding History

Wexford Capital’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,879
Closed -$250K – 231
2024
Q4 		$250K Sell
17,879
-17,000
-49% -$364K 0.04% 150
2024
Q3 		$789K Sell
34,879
-10,000
-22% -$231K 0.19% 81
2024
Q2 		$908K Buy
44,879
+10,000
+29% +$226K 0.23% 70
2024
Q1 		$868K Hold
34,879
– – 0.18% 95
2023
Q4 		$631K Buy
+34,879
New +$577K 0.14% 90

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Wexford Capital's BCYC Position: Q1 2025 in Review

Wexford Capital sold out of Bicycle Therapeutics (BCYC) in Q1 2025, closing a stake of 17,879 shares — an estimated $250K sold.

Wexford Capital first reported a position in BCYC in Q4 2023 and held it in 5 quarters. The position peaked at $908K in Q2 2024. 95 funds tracked by Wall St. Rank hold BCYC as of Q1 2025.

  • Wexford Capital reported no remaining Bicycle Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Wexford Capital sold 17,879 Bicycle Therapeutics shares in Q1 2025, an estimated $250K.
  • Wexford Capital first reported a position in Bicycle Therapeutics in Q4 2023 and held it in 5 quarters.
  • Wexford Capital's Bicycle Therapeutics position peaked at $908K in Q2 2024.
  • 95 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2025.

Based on Wexford Capital's 13F filing for Q1 2025, filed 15 May 2025.